Neuroprotective Effects of the Psychoactive Compound Biatractylolide (BD) in Alzheimer’s Disease

Qianmei Hu 1,†, Jixiang Wang 1,†, Maida Irshad 1, Siyu Mao 1, Hongting Chen 2, Yujiao Song 1, Xuan Xu 1 and Xing Feng 1,∗

1 The Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, and Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha 410013, China
2 College of Letters & Science, University of California, Berkeley, CA 94720, USA
∗ Correspondence: fengxing@hunnu.edu.cn; Tel.: +86-13875868872
† These authors contributed equally to this work.

Abstract: Mitochondria play a central role in the survival or death of neuronal cells, and they are regulators of energy metabolism and cell death pathways. Many studies support the role of mitochondrial dysfunction and oxidative damage in the pathogenesis of Alzheimer’s disease. Biatractylolide (BD) is a kind of internal symmetry double sesquiterpene novel ester compound isolated from the Chinese medicinal plant Baizhu, has neuroprotective effects in Alzheimer’s disease. We developed a systematic pharmacological model based on chemical pharmacokinetic and pharmacological data to identify potential compounds and targets of Baizhu. The neuroprotective effects of BD in PC12 (rat adrenal pheochromocytoma cells) and SH-SY5Y (human bone marrow neuroblastoma cells) were evaluated by in vitro experiments. Based on the predicted results, we selected 18 active compounds, which were associated with 20 potential targets and 22 signaling pathways. Compound-target, target-disease and target-pathway networks were constructed using Cytoscape 3.2.1. And verified by in vitro experiments that BD could inhibit Aβ by reducing oxidative stress and decreasing CytC release induced mPTP opening. This study provides a theoretical basis for the development of BD as an anti-Alzheimer’s disease drug.

Keywords: traditional Chinese medicine; biatractylolide; neuroprotective; pharmacological model; network pharmacology

1. Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disease in the elderly [1,2]. This disease causes severe cognitive impairment and is accompanied by classic pathological changes. Such as amyloid beta (Aβ) deposition in the brain parenchyma, blood vessels [3–5], formation of neurofibrillary tangles [6–9], and loss of neurons [10]. Clinically, the silent period of the disease may last for decades [11], with some symptoms lasting 5 to 10 years [12,13].

Aβ plaques, or possibly soluble oligomers of Aβ, are neurotoxic and act by disrupting mitochondrial function, inducing apoptosis, forming ion channels and stimulating stress-activated protein kinase pathways [14]. It has been shown that Aβ-mediated mitochondrial dysfunction is due to the activated mitochondrial permeability transition pore (mPTP), which increases mitochondrial membrane permeability [15,16]. The mPTP is known to consist of voltage-dependent anion channels, adenine nucleotide transporters and cell cycle protein D (CypD) [17,18]. CypD is critical in stabilising the mitochondrial permeability transition which acts to switch on mPTP. Aβ can accumulate in mitochondria, in which it interacts with ABAD and CypD [19–21], this interaction promotes ROS leakage and ultimately leads to mitochondrial dysfunction [22–25]. Increased permeability of the mitochondrial membrane after the opening of mPTP [15] leads to the rupture of the outer mitochondrial membrane, followed by the diffusion of contents such as calcium and CytC from the mitochondrial matrix into the cytoplasm, where they eventually trigger cell death [26–28]. Thus
Aβ impairs mPTP function by disrupting the mitochondrial membrane potential [29] and increasing ROS production, mitochondrial swelling and CytC release [30–32], ultimately leading to cell death.

A number of approaches have been explored to protect mitochondria from Aβ-induced damage, including elimination of ROS [33] enhancement of clearance [34,35] and stabilization of calcium homeostasis [36]. Research that block the formation of large amounts of mPTP are advantageous compared to strategies that focus primarily on injury prevention by eliminating damage-causing factors [37,38]. In the search for more novel therapeutic agents, the laboratory focused on traditional Chinese herbs.

Baizhu is a traditional Chinese herb with roots possessing various pharmacological activities such as antioxidant [39], gastric protection [40], antitumour [41] and anti-AD [42,43]. Biatractylolide (BD) is a novel bisesquiterpene lactone isolated from the Chinese medicinal plant Atractylodes macrocephala (Baizhu). According to previous studies, BD has a pronounced effect on reducing acetylcholinesterase activity and improving memory in mice with aluminium trichloride induced dementia. It could significantly reduce acetylcholinesterase activity in a rat AD model induced by Aβ1−40 and improve behavior and memory. Therefore, BD showed promising potential to be an effective anti-AD drug [44].

The leading model of “one gene, one target, one disease” has been found to influence drug discovery [45], with many effective drugs working on multiple targets rather than a single target. Thus, network pharmacology provides a new network model for multiple targets, multiple effects, and complicated diseases [46,47].

In the present study, we developed a systems pharmacology-based model to screen potential compounds and targets and applied compound-target (C-T) and target-disease (T-D) networks to assess the mechanism of action. The neuroprotective effect of BD against Aβ-induced oxidative stress was assessed by in vitro experiments using Aβ25−35 [48] peptide in rat adrenal pheochromocytoma cells (PC12) and human myeloid neuroblastoma cell line (SH-SY5Y) to mimic Aβ-induced neurodegeneration.

2. Results
2.1. MTT Assay

The MTT assay was used in order to investigate the therapeutic effect of BD on Aβ25−35-induced cell damage (Figure 1). The cell viability treated with Aβ25−35 was significantly reduced. After pretreatment with different concentrations of BD (5 μM, 10 μM and 20 μM, respectively) for two hours followed by treatment with Aβ25−35, the cell viability of SH-SY5Y cells was significantly increased. Cell viability increased to 90.5 ± 0.3% at a BD concentration of 20 μM. After pretreatment with BD, the cell viability of PC12 cells also increased significantly, increasing to 82.2 ± 1.4% at a BD concentration of 20 μM. This result suggests that BD has a significant effect on improving cell viability in both cell.

![Figure 1](image-url)
2.2. Detection of MMP by Rhodamine 123 Staining

After treatment with 20 μM Aβ25-35, MMP was considerably decreased as compared with the control (p < 0.001) (Figure 2). Pretreatment with BD (5, 10, and 20 μM) could significantly protect PC12 and SH-SY5Y cells from the effects of reduced MMP by Aβ25-35. In PC12 cells, the MMP increased to 76.7 ± 2.4%, 84.9 ± 1.0%, and 91.6 ± 0.7%, respectively, after BD (5 μM, 10 μM and 20 μM, respectively) pretreatment. In SH-SY5Y cells, MMP increased to 78.7 ± 2.0%, 81.8 ± 1.0%, 86.8 ± 1.2%, respectively, after BD (5 μM, 10 μM and 20 μM, respectively) pretreatment.

Figure 2. Effect of Aβ25-35 mitochondrial membrane potential (MMP) in PC12 and SH-SY5Y cell lines with BD treatment. The two cell lines were treated with low, medium, high, concentrations of BD, then MMP was examined by rhodamine 123 staining. (** p < 0.01 vs. control, * p < 0.05, ** p < 0.01 vs. treated).

2.3. Measurement of Intracellular ROS

The effects of different concentrations of BD on ROS release in cells were investigated (Figure 3). With treatment, relative fluorescence of ROS was increased in SH-SY5Y and PC12 cells as compared to controls. Pretreatment with BD at 5, 10, 20 μM, however, significantly inhibited relative fluorescence intensity of ROS to 149.5 ± 4.5%, 118.5 ± 2.5%, 112.5 ± 6.5% in PC12 cells as compared with Aβ25-35 treatment (p < 0.01). In addition, BD (5, 10, and 20 μM) gradually decreased ROS production to 174.5 ± 4.5%, 139 ± 1.0%, 119 ± 2.0% in SH-SY5Y cells as compared with Aβ25-35 treatment.

2.4. Protein Characterization

For mPTP opening, CypD is an important factor that combines with VDAC and ANT and forms mPTP. The opening of mPTP causes the release of the pro-apoptotic factor CytC from the mitochondrial matrix to the cytoplasm. To validate the protective effects of BD on Aβ25-35-induced PC12 and SH-SY5Y cells, we further analyzed protein characterization by western blot analysis. BD treatment could reduce Aβ25-35–induced CytC release (Figure 4). Aβ25-35 treatment significantly increased CytC in cytosol (* p < 0.05) while after BD treatment the level of CytC was significantly reduced (p < 0.01).
Figure 3. Fluorescence intensity of reactive oxygen species in PC12 and SH-SY5Y cells treated with Aβ25-35. Cells were treated with 5 μM, 10 μM and 20 μM BD for 2 h, followed by Aβ25-35 for 24 h. (a): PC12; (b): SH-SY5Y. The bar chart shows the quantitative data. (c): PC12; (d): SH-SY5Y. (** p < 0.01 vs. control, # p < 0.05, ## p < 0.01 vs. treated).
Figure 4. Effects of BD on the expression of CypD and CytC protein in PC12 and SH-SY5Y cells induced by Aβ_{25-35}. (a): The expression of CypD and CytC protein in PC12 cells; (b): CypD and CytC protein expression in SH-SY5Y cells. CypD and CytC were quantified by treating cells with BD at different concentrations for 2 h before treatment with Aβ_{25-35} for 24 h; (c,e,g): CypD and CytC quantification in PC12 cells; (d,f,h): CypD and CytC quantification in SH-SY5Y cells, which is proportional to β-actin level. (*p < 0.05, **p < 0.01, ***p < 0.005 vs. control. #p < 0.05, ##p < 0.01, ###p < 0.005 vs. treated).
2.5. Networks

2.5.1. Active Compound Screening

We screened 18 active compounds with their 388 potential targets by using OB ≥ 25%, DL ≥ 0.1, Caco-2 cell permeability ≥ 0.4. Furthermore, we screened 20 targets that are related to most compounds (Figure 5).

![Figure 5. Network of all (55) compounds of Baizhu.](image)

2.5.2. Network Construction and Analysis: C-T Network

We build a C-T network based on the candidate compounds of Baizhu and potential targets. The C-T network included 18 nodes (18 candidate compounds) and 20 edges (20 latent targets) (Figure 6).

![Figure 6. C-T network. The light red diamonds are the compounds and the light blue circles are the targets. The difference in size shows the number of compounds to which the target is connected.](image)
2.5.3. T-D Network

To better comprehend the diseases modified by Baizhu, we searched the Drug Bank and TTD databases for latent targets to find corresponding diseases. The 78 diseases were categorized into 10 groups on the grounds of MeSH Browser (2014 version). And the T-D network was structured by potential targets and their corresponding diseases. Lots of defined diseases belong to the diseases of central nervous system (24/78), bone and joint (14/78) or digestive system (13/78) (Figure 7). For instance, PTGS2, MAPT, and GABRA1 are critical targets of leukodystrophy and are associated with AD, neuropathic pain, and cognitive impairment in the T-D network (Figure 7).

![Figure 7. T-D network. Green 20 circles represent the targets of Baizhu. The 10 red octagons represent systems and 78 yellow “V”s represent diseases.](image)

2.5.4. Target-Pathway (T-P) Network

To explore the regulation of Baizhu for treating AD, pathways were assembled by using Cytoscape (Figure 8) based on current knowledge of pathogenesis. The potential human target proteins were searched in the KEGG pathway and GO databases. KEGG pathways included oxidative, metabolic, calcium signaling, and PI3K-Akt signaling pathways. These pathways are related to AD. According to the pathways we found, Baizhu could alleviate the severity of AD by their inhibition (↓ROS).

![Figure 8. T-P network. Green hexagonals represent targets and purple rectangles represent pathways.](image)
3. Discussion

In this study, we developed a systematic pharmacological model based on chemical, pharmacokinetic and pharmacological data to identify potential compounds and targets of the traditional Chinese medicine Atractylodes macrocephala with AD neuroprotective effects. We selected 18 active compounds associated with 20 potential targets and 22 signaling pathways by OB screening and DL and Caco-2 cell permeability evaluation, and successfully constructed C-T, T-D and target pathway networks using Cytoscape 3.2.1. We also demonstrated in cellular experiments that BD can inhibit the effects of Aβ25-35-induced cell damage and inhibit the reduction of MMP; BD can reduce the production of ROS in SH-SY5Y cells, and BD treatment can reduce Aβ25-35-induced CytC release by WB experiments. BD is a promising novel compound for the treatment of Alzheimer’s disease.

At present, due to the aging of the population, the prevalence of AD is increasing, putting a very high pressure on society and families [49,50]. However, the pathogenesis of AD has not been clearly interpreted and valid therapy is still lacking. Aβ is one of the hallmarks [51] of MMP. Aβ itself causes oxidative stress but also increases the oxidative stress produced by others that leads to mPTP opening. mPTP, when formed, constitutes a non-selective, highly conductive pore that allows calcium transport and also transport of any solute below the pore size. This leads to mitochondrial osmotic swelling and MMP dissipation, impairing the mitochondrial respiratory chain, resulting in decreased adenosine triphosphate production and increased ROS production. Second, mitochondrial swelling result in rupture of the outer membrane, allowing the release of apoptogenic factors such as CytC from the mitochondria to the cell membrane (Figure 9).

Figure 9. Proposed mechanism of action of biatractylolide (BD). Aβ deposition causes reactive oxygen species (ROS) production, which leads to a change in mitochondrial membrane potential (MMP), opening of mitochondrial permeability transition pore (mPTP), allowing release of CytC (apoptotic factor) into cytosol. BD decreases the production of ROS and inhibits the opening of mPTP. IMM, inner membrane; OMM, outer membrane.

Many approaches have been investigated to protect mitochondria against Aβ-induced injury, such as eliminating ROS [33], strengthening Aβ clearance [34,35] and regulating calcium balance [36,37]. Strategies that focus on preventing mitochondrial insult by blocking large amounts of mPTP formation are advantageous because they can improve mitochondrial resistance to existing damage. Mitochondrial targeted therapies that ameliorate mitochondrial function may hold great promise in preventing and treating AD.

Chinese herbal medicine has been considered one of the most momentous tactics in complementary and alternative medicine. Also, network pharmacology has become a effective tool to comprehend drug targeting, particularly for the various components of Chinese herbal medicine. From Baizhu (Chinese herbal medicine) via ADME prescreening (TCMSP), we identified 18 candidate compounds with 388 (Swiss Target Prediction) potential targets possessing favorable pharmacokinetic profiles. Then we focused on 20 targets that are
related to most compounds. We created three networks: (1) C-T network, with effective constituent of Baizhu and its corresponding targets used (TCMSP, Swiss Target Prediction); (2) T-D network, with all targets and their corresponding diseases used (TTD, Drug bank); and (3) target-pathway network (T-P network), using target information extracted from the KEGG database and the T-P network constructed from targets and their corresponding assumed pathways. All visualized network diagrams were built with Cytoscape 3.2.1 (http://www.cytoscape.org/, accessed on 3 November 2022), an open software package project for visualizing, integrating, modeling and analyzing interaction networks [52].

From the results, the Chinese herbal medicine Baizhu may have a protective effect on CNS and other systems. BD (M62) is one ingredient of Baizhu that has a protective effect in AD [43]. It has antioxidant activity, inhibits the opening of mPTP and decreases MPT-dependent CytC release. So it could have a neuroprotective effect in AD. Furthermore, we used PC12 and SH-SY5Y cell lines and found increased cell viability by using preliminary BD against Aβ25-35–damaged cells.

4. Materials and Methods

4.1. Materials

BD was isolated from the ethyl acetate extract of A. macrocephala (Baizhu) by multistep chromatographic processing (Figure 10). Aβ25-35 and DMSO were from Sigma Chemicals (USA). Antibodies for the proteins CypD, CytC and β-actin were from Protein Tech.

![Figure 10. Chemical structure of biatractylolide (BD). Molecular formula: C30H38O4, molecular weight: 462.63 g/mol.](image)

4.2. Data Set Construction

We used the literature published in the previous 32 years available in the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and analysis platform (http://sm.nwsuaf.edu.cn/lsp/tcmsp.php, accessed on 3 November 2022) and the Swiss Target Prediction (http://www.swisstargetprediction.ch/, accessed on 3 November 2022). We searched corresponding targets and A. macrocephala from the TCMSP database.

4.3. Active Compound Screening

Initially we searched the Total-55 compounds for Baizhu drug and their corresponding targets. Then we used oral bioavailability (OB) screening with drug-likeness (DL) and Caco-2 cell permeability evaluation to identify the active compounds in Baizhu. We selected 18 compounds with OB ≥ 25%, DL ≥ 0.1, Caco-2 permeability ≥ 0.4 that exhibited extensive [53] pharmacological activities as candidate active compounds for further research.

4.4. Network Construction

Compound-target (C-T) and target-disease (T-D) networks according to Cytoscape 3.2.1 were used to identify potential drugs and their corresponding mechanisms using a compound-target-disease association approach. The C-T network was generated by linking screened candidate compounds to potential targets. The T-D network was constructed by linking relevant targets to diseases. Potential diseases were obtained from the Therapeutic Target Database (TTD; http://bidd.nus.edu.sg, accessed on 3 November 2022) and DrugBank (https://www.drugbank.ca/, accessed on 3 November 2022).
4.5. Pathway Analysis

Signaling pathways, as an important component of pharmacology, link receptor ligand interactions to pharmacodynamics outputs [54]. First, we obtained the details of the human target proteins and then analyzed their functions and pathways by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway analysis (KEGG, http://www.genome.jp/kegg/, accessed on 3 November 2022), respectively. Then based on this basic information, pathways related to the central nervous system (CNS; AD) pathology were assembled by using Cytoscape.

4.6. Cell Culture

PC12 (rat adrenal pheochromocytoma cell) and SH-SY5Y (human bone marrow neuroblastoma cell line) cells provided by Dr. James R. Woodgett (China Pharmaceutical University, Nanjing, China) were cultured in DMEM medium in the presence of 10% fetal bovine serum and 1% double antibody. All cells were cultured at 37 °C in a humidified 5% CO₂ incubator.

4.7. Experimental Grouping and Drug Treatment

After adding different concentrations of Aβ25-35 in the preliminary experiment, by determining dose-response curves, we selected 20 µM (concentration) as the most optimal damage concentration. The experiment was as follows: (1) blank control group, (2) Aβ injury model group and (3) drug treatment group (low, medium and high).

4.8. Cell Viability Assay (MTT)

Cells were cultured in 96-well plates for 48 h and then pretreated with different concentrations of BD (5, 10, 20 µM) for two hours before adding Aβ25-35 and reacting for 24 h. 50 µL of MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazole) was added to each well and incubated for 5 h at 37 °C. Next, the medium was discarded and 150 µL of DMSO per well was added to dissolve the formazan crystals. Cell viability was measured by measuring absorbance at 490 nm using a Dynatech MR5000 plate reader.

4.9. Detection of MMP by Rhodamine 123 Staining

The opening of the mPTP in PC12 and SH-SY5Y cells was assessed by using rhodamine 123 staining. PC12 (2 × 10⁵) cells and SH-SY5Y (3 × 10⁵) cells were seeded in 24-well plates and cultured overnight. Then cells were treated with various concentrations of BD (5, 10, 20 µM) for 2 h before Aβ25-35 treatment for 24 h in an incubator. Treated cells were harvested and resuspended in the medium, then incubated with rhodamine 123 (10 mg/mL) at 37 °C in a humidified 5% CO₂ incubator for 10–15 min at room temperature in the dark, then observed by fluorescence microscopy.

4.10. Measurement of Intracellular ROS

PC12 cells and SH-SY5Y cells were seeded in 6-well culture plates at 1 × 10⁵/well and cultured overnight. Then cells were treated with 5, 10, and 20 µM BD for 2 h before Aβ treatment for 24 h in an incubator. Next, treated cells were washed with cold PBS twice and fixed with formaldehyde for 30 min according to ROS assay kit instructions (Beyotime Biotechnology). Intracellular ROS contents were observed by fluorescence microscopy.

4.11. Western Blot Analysis (CYPD, CytC)

Western blot assays were performed as described by Su et al. [55]. Cellular proteins were extracted, and sample proteins were separated on SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (PVDF). The membranes were incubated with the primary antibody overnight at 4 °C and then incubated with the secondary antibody for 1 h at room temperature. Finally, reaction bands were observed using Pierce Super Signal Chemiluminescent Substrate (Rockford, IL, USA) and proteins were quantified using Image J.
4.12. Statistical Analysis

All quantitative data are expressed as mean ± SEM. Statistical differences between the groups were assessed by one-way ANOVA. *p* < 0.05 was considered statistically significant. Statistical analysis involved using GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA).

5. Conclusions

Mitochondrial oxidative injury plays a crucial role in the pathogenesis of multiple neurodegenerative diseases including AD. Hence, approaches to prevent or decrease oxidative damage may offer treatment efficacy. We proofed that biatractylolide overexpression inhibited Aβ-induced mPTP opening by reducing oxidative stress and decreased CytC release. We also used systems pharmacology to understand the pharmacological mechanism and active substances of traditional Chinese medicine. This study defines possible therapeutic targets for AD treatment, although further experiments are needed to support this.

Author Contributions: X.F. conceived, directed and supervised the research project; Q.H., J.W., M.I. designed the experimental methods; Q.H., J.W., M.I., S.M., H.C., Y.S. and X.X. performed the experiments and collected the data; S.M., H.C. and Y.S. analyzed the data for statistical applications. Q.H., J.W. and M.I. prepared the manuscript; Q.H. and J.W. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Hunan Natural Science Foundation (2020JJ4438), the Key Project of Developmental Biology and Breeding from Hunan Province (2022XKQ0205) and Hunan Normal University undergraduates innovative experiment project and entrepreneurship program (2019107) and Hunan province college students research learning and innovative experiment project (S202110542052).

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984, 34, 939–944. [CrossRef]
2. Erwin, W.G. Senile dementia of the Alzheimer type. Clin. Pharm. 1984, 3, 497–504. [CrossRef] [PubMed]
3. Selkoe, D.; Podlisny, M.; Joachim, C.; Vickers, E.; Lee, G.; Fritz, L.; Oltersdorf, T. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc. Natl. Acad. Sci. USA 1988, 85, 7341–7345. [CrossRef]
4. Goedert, M.; Spillantini, M.G. Molecular neuropathology of Alzheimer’s disease: In situ hybridization studies. Cell. Mol. Neurobiol. 1990, 10, 159–174. [CrossRef]
5. Pereira, C.; Agostinho, P.; Moreira, P.I.; Cardoso, S.M.; Oliveira, C.R. Alzheimer’s disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr. Drug Targets CNS Neurol. Disord. 2005, 4, 383–403. [CrossRef]
6. Thangavel, R.; Sahu, S.K.; Van Hoesen, G.W.; Zaheer, A. Loss of nonphosphorylated neurofilament immunoreactivity in temporal cortical areas in Alzheimer’s disease. Neuroscience 2009, 160, 427–433. [CrossRef]
7. Ball, M.J. Neurofibrillary tangles in the dementia of “normal pressure” hydrocephalus. Can. J. Neurol. Sci. 1976, 3, 227–235. [CrossRef]
8. Nishiyama, A.; Kato, T.; Ito, S.; Sato, M.; Minamitani, Y.; Hori, H.; Morita, M.; Matsuda, T.; Inagaki, M.; et al. Amyloid-beta peptide and the development of Alzheimer's disease. Neurosci. Res. 2008, 60, 181–191. [CrossRef] [PubMed]
13. Yuyama, K.; Sun, H.; Usuki, S.; Sakai, S.; Hanamatsu, H.; Mioka, T.; Kimura, N.; Okada, M.; Tahara, H.; Furukawa, J.; et al. A potential function for neuronal exosomes: Sequestering intracellular amyloid-β peptide. FEBS Lett. 2015, 589, 84–88. [CrossRef]
14. Tillement, L.; Lecanu, L.; Papadopoulos, V. Alzheimer’s disease: Effects of β-amyloid on mitochondria. Mitochondrion 2011, 11, 13–21. [CrossRef]
15. Ren, R.; Zhang, Y.; Li, B.; Wu, Y.; Li, B. Effect of β-amyloid (25-35) on mitochondrial function and expression of mitochondrial permeability transition pore proteins in rat hippocampal neurons. J. Cell. Biochem. 2011, 112, 1450–1457. [CrossRef] [PubMed]
16. Sheehan, J.P.; Swerdlov, R.H.; Miller, S.W.; Davis, R.E.; Parks, J.K.; Parker, W.D.; Tuttle, J.B. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer’s disease. J. Neurosci. 1997, 17, 4612–4622. [CrossRef] [PubMed]
17. Tsujimoto, Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J. Cell. Physiol. 2003, 195, 158–167. [CrossRef]
18. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; et al. ABAD directly links Abeta to mitochondrial dysfunction in Alzheimer’s disease. Science 2004, 304, 448–452. [CrossRef]
19. Takuma, K.; Yao, J.; Huang, J.; Xu, H.; Chen, X.; Luddy, J.; Trillat, A.C.; Stern, D.M.; Arancio, O.; Yan, S.S. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. Faseb J. 2005, 19, 597–598. [CrossRef]
20. Du, H.; Guo, L.; Fang, F.; Chen, D.; Sosunov, A.A.; McKhann, G.M.; Yan, Y.; Wang, C.; Zhang, H.; Molkentin, J.D.; et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat. Med. 2008, 14, 1097–1105. [CrossRef]
21. Du, H.; Guo, L.; Zhang, W.; Rydzewska, M.; Yan, S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol. Aging 2011, 32, 398–406. [CrossRef] [PubMed]
22. Valasani, K.R.; Hu, G.; Chaney, M.O.; Yan, S.S. Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD for treatment of Alzheimer’s disease. Chem. Biol. Drug Des. 2013, 81, 238–249. [CrossRef]
23. Valasani, K.R.; Chaney, M.O.; Day, V.W.; Shidu Yan, S. Acetylcholinesterase inhibitors: Structure based design, synthesis, pharmacophore modeling, and virtual screening. J. Chem. Inf. Model. 2013, 53, 2033–2046. [CrossRef] [PubMed]
24. Smith, M.A.; Perry, G.; Richey, P.L.; Sayre, L.M.; Anderson, V.E.; Beal, M.F.; Kowall, N. Oxidative damage in Alzheimer’s. Brain Pathol. 2003, 13, 21–29. [CrossRef]
25. Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Trends Mol. Med. 2008, 14, 45–53. [CrossRef] [PubMed]
26. Reddy, P.H.; Beal, M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol. Med. 2008, 14, 173–186. [CrossRef]
27. Rui, Y.; Tiwari, P.; Xie, Z.; Zheng, J.Q. Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J. Neurosci. 2006, 26, 10480–10487. [CrossRef] [PubMed]
28. Rosenstock, T.R.; Carvalho, A.C.; Jurkiewicz, A.; Frassa-Filho, R.; Smaili, S.S. Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid. J. Neurochem. 2004, 88, 1220–1228. [CrossRef]
29. Reddy, P.H.; Beal, M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol. Med. 2008, 14, 45–53. [CrossRef] [PubMed]
30. Rui, Y.; Tiwari, P.; Xie, Z.; Zheng, J.Q. Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J. Neurosci. 2006, 26, 10480–10487. [CrossRef] [PubMed]
31. Du, H.; Guo, L.; Wu, X.; Sosunov, A.A.; McKhann, G.M.; Chen, J.X.; Yan, S.S. Cyclophilin D deficiency rescues Aβ-impaired PKA/CREB signaling and alleviates synaptic degeneration. Biochim. Biophys. Acta 2014, 1842, 2517–2527. [CrossRef]
32. Chin, J.H.; Tse, F.W.; Harris, K.; Jiananddas, J.H. Beta-amyloid enhances intracellular calcium rises mediated by repeated activation of intracellular calcium stores and nicotinic receptors in acutely dissociated rat basal forebrain neurons. Brain Cell Biol. 2006, 35, 173–186. [CrossRef]
33. Yang, X.; Yang, Y.; Li, G.; Wang, J.; Yang, E.S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin1 mutation. J. Mol. Neurosci. 2008, 34, 165–171. [CrossRef]
34. Miners, J.S.; Baig, S.; Palmer, J.; Palmer, L.E.; Kehoe, P.G.; Love, S. Abeta-degrading enzymes in Alzheimer’s disease. Brain Pathol. 2008, 18, 240–252. [CrossRef] [PubMed]
35. Schroeter, S.; Khan, K.; Barbour, R.; Doan, M.; Chen, M.; Guido, T.; Gill, D.; Basi, G.; Schenk, D.; Seubert, P.; et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 2008, 28, 6787–6793. [CrossRef]
36. Chipana, C.; Camarasa, J.; Pubill, D.; Escudebro, E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 2008, 29, 179–183. [CrossRef]
37. Diehl-Schmid, J.; Förstl, H.; Perneckzy, R.; Pohl, C.; Kurz, A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int. J. Geriatr. Psychiatry 2008, 23, 754–759. [CrossRef]
38. Yang, X.; Wang, Y.; Luo, J.; Liu, S.; Yang, Z. Protective effects of YC-1 against glutamate induced PC12 cell apoptosis. Cell. Mol. Neurobiol. 2011, 31, 303–311. [CrossRef]
39. Wang, K.; Zhu, X.; Zhang, K.; Zhou, F.; Zhu, L. Gas1 Knockdown Increases the Neuroprotective Effect of Gliath Cell-Derived Neurotrophic Factor Against Glutamate-Induced Cell Injury in Human SH-SY5Y Neuroblastoma Cells. Cell. Mol. Neurobiol. 2016, 36, 603–611. [CrossRef] [PubMed]
40. Wang, K.T.; Chen, L.G.; Chou, D.S.; Liang, W.L.; Wang, C.C. Anti-Oxidative Abilities of Essential Oils from Atractylodes ovata Rhizome. Evid.-Based Complement. Altern. Med. 2011, 2011, 204892. [CrossRef]
41. Wang, K.T.; Chen, L.G.; Wu, C.H.; Chang, C.C.; Wang, C.C. Gastroprotective activity of atractylenolide III from Atractylodes ovata on ethanol-induced gastric ulcer in vitro and in vivo. *J. Pharm. Pharm.* 2010, 62, 381–388. [CrossRef] [PubMed]
42. Liu, Y.; Jia, Z.; Dong, L.; Wang, R.; Qiu, G. A randomized pilot study of atractylenolide I on gastric cancer cachexia patients. *Evid.-Based Complement. Altern. Med.* 2008, 5, 337–344. [CrossRef]
43. Zhu, L.; Ning, N.; Li, Y.; Zhang, Q.F.; Xie, Y.C.; Irshad, M.; Feng, X.; Tao, X.J. Biatractylolide Modulates PI3K-Akt-GSK3β-Dependent Pathways to Protect against Glutamate-Induced Cell Damage in PC12 and SH-SYSY Cells. *Evid.-Based Complement. Altern. Med.* 2017, 2017, 1291458. [CrossRef] [PubMed]
44. Xie, Y.C.; Ning, N.; Zhu, L.; Li, D.N.; Feng, X.; Yang, X.P. Primary Investigation for the Mechanism of Biatractylolide from Atractylodis Macrocephalae Rhizoma as an Acetylcholinesterase Inhibitor. *Evid.-Based Complement. Altern. Med.* 2016, 2016, 7481323. [CrossRef] [PubMed]
45. Sams-Dodd, F. Target-based drug discovery: Is something wrong? *Drug Discov. Today* 2005, 10, 139–147. [CrossRef]
46. Roth, B.L.; Sheffler, D.J.; Kroeze, W.K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. *Nat. Rev. Drug Discov.* 2004, 3, 353–359. [CrossRef][PubMed]
47. Li, S.; Zhang, B. Traditional Chinese medicine network pharmacology: Theory, methodology and application. *Chin. J. Nat. Med.* 2013, 11, 110–120. [CrossRef]
48. Lin, C.I.; Chang, Y.C.; Kao, N.J.; Lee, W.J.; Cross, T.W.; Lin, S.H. 1,25(OH)(2)D(3) Alleviates Aβ(25-35)-Induced Tau Hyperphosphorylation, Excessive Reactive Oxygen Species, and Apoptosis Through Interplay with Glial Cell Line-Derived Neurotrophic Factor Signaling in SH-SYSY Cells. *Int. J. Mol. Sci.* 2020, 21, 4215. [CrossRef]
49. Zhang, L.; Han, L.; Wang, X.; Wei, Y.; Zheng, J.; Zhao, L.; Tong, X. Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking. *Biosci. Rep.* 2021, 41, BSR20203520. [CrossRef] [PubMed]
50. Iyengar, R.; Zhao, S.; Chung, S.W.; Mager, D.E.; Gallo, J.M. Merging systems biology with pharmacodynamics. *Sci. Transl. Med.* 2012, 4, 126ps127. [CrossRef]
51. Su, Q.; Peng, M.; Zhang, Y.; Xue, W.; Darko, K.O.; Tao, T.; Huang, Y.; Tao, X.; Yang, X. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. *Am. J. Cancer Res.* 2016, 6, 498–508. [PubMed]
52. Modi, K.K.; Jana, A.; Ghosh, S.; Watson, R.; Pahan, K. A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer’s disease. *PLoS ONE* 2014, 9, e103606. [CrossRef] [PubMed]
53. Zhang, Q.S.; Liu, W.; Lu, G.X. miR-200a-3p promotes b-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer’s disease. *J. Biosci.* 2017, 42, 397–404. [CrossRef]
54. Siedlak, S.L.; Casadesus, G.; Webber, K.M.; Pappolla, M.A.; Atwood, C.S.; Smith, M.A.; Perry, G. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer’s disease. *Free Radic. Res.* 2009, 43, 156–164. [CrossRef]
55. Smoot, M.E.; Ono, K.; Ruscheinski, J.; Wang, P.L.; Ideker, T. Cytoscape 2.8: New features for data integration and network visualization. *Bioinformatics* 2011, 27, 431–432. [CrossRef]